Budesonide; formoterol fumarate; glycopyrrolate - Generic Drug Details

What are the generic drug sources for budesonide; formoterol fumarate; glycopyrrolate and what is the scope of freedom to operate?

Budesonide; formoterol fumarate; glycopyrrolate is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Budesonide; formoterol fumarate; glycopyrrolate has two hundred and seventeen patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for budesonide; formoterol fumarate; glycopyrrolate

International Patents:	217
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for budesonide; formoterol fumarate; glycopyrrolate
DailyMed Link:	budesonide; formoterol fumarate; glycopyrrolate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for budesonide; formoterol fumarate; glycopyrrolate

Constraining patent/regulatory exclusivity:

8,703,806

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for budesonide; formoterol fumarate; glycopyrrolate

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for budesonide; formoterol fumarate; glycopyrrolate

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03CC	Selective beta-2-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for budesonide; formoterol fumarate; glycopyrrolate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	11,833,292		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,815,258
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	11,331,442		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,324,266
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	10,716,753		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	9,415,009

International Patents for budesonide; formoterol fumarate; glycopyrrolate

Country	Patent Number	Title	Estimated Expiration
Cyprus	1122807
South Korea	20200070284
Cyprus	1118030
Japan	2020536622
Mexico	337126
South Korea	102683072

Supplementary Protection Certificates for budesonide; formoterol fumarate; glycopyrrolate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	132021000000095	Italy		PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
2435024	PA2021511	Lithuania		PRODUCT NAME: FORMOTEROLIO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS), GLIKOPIROLATO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENANTIOMERUS) IR BUDEZONIDO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS) DERINYS; REGISTRATION NO/DATE: EU/1/20/1498 20201209
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435025	36/2019	Austria		PRODUCT NAME: GLYCOPYRRONIUMBROMID / FORMOTEROL; REGISTRATION NO/DATE: EU/1/18/1339 (MITTEILUNG) 20181220
2435025	201940030	Slovenia		PRODUCT NAME: COMBINATION OF GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES) AND FORMOTEROLE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES); NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF NATIONAL AUTHORISATION: 20181218; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515

Market Dynamics and Financial Trajectory for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Last updated: December 17, 2025

Executive Summary

The combination therapy comprising Budesonide, Formoterol Fumarate, and Glycopyrrolate targets respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The evolving landscape of pulmonary therapeutics, driven by rising prevalence of respiratory diseases, regulatory approvals, and technological innovations, shapes the market dynamics. The anticipated growth trajectory is influenced by patent expirations, entry of biosimilars and generics, alongside increasing healthcare expenditures and unmet clinical needs.

Projected to expand at a compounded annual growth rate (CAGR) of approximately 6-8% over the next five years, the market's financial outlook indicates lucrative opportunities for existing pharmaceutical players and novel entrants.

This comprehensive analysis delineates key drivers, competitive landscape, regulatory factors, and forecasts to aid stakeholders in strategic decision-making.

---

Table of Contents

1. Market Overview and Composition
2. Key Drivers and Challenges
3. Regulatory Landscape and Approvals
4. Competitive Landscape and Major Players
5. Financial Projections and Revenue Streams
6. Market Segmentation and Geographic Trends
7. Emerging Innovation and Pipeline Developments
8. Strategic Implications for Stakeholders
9. Key Takeaways
10. FAQs

---

1. Market Overview and Composition

The drug combination of Budesonide, Formoterol Fumarate, and Glycopyrrolate primarily targets COPD and asthma management, offering a triple-bronchodilator and anti-inflammatory effect. The market comprises:

Component	Role	Approval Status	Key Brands (examples)
Budesonide	Inhaled corticosteroid (ICS)	Widely approved globally	Pulmicort (AstraZeneca)
Formoterol Fumarate	Long-acting beta-agonist (LABA)	Approved for COPD and asthma	Foradil, Performist
Glycopyrrolate	Long-acting anticholinergic (LAMA)	Approved for COPD	Seebri, Lonhala

The combined formulations, notably Ulonia (GSK's triple therapy) and Trimbow (Chiesi), exemplify the therapeutic synergy.

2. Key Drivers and Challenges

Drivers

• Rising disease prevalence: According to WHO, over 300 million individuals have asthma, and COPD affects approximately 250 million globally [1].
• Innovation in inhaler delivery systems: DPI and MDI devices enhance adherence.
• Expanding indications and labels: Regulatory approvals for specific populations and conditions foster growth.
• Healthcare policy shifts: Emphasis on inhaler therapies to reduce hospitalization rates.

Challenges

• Patent expirations: Leading brands may face generic competition, affecting margins.
• Pricing pressures: Governmental regulations curb prices in mature markets.
• Patient adherence issues: Complex inhaler devices can reduce compliance.
• Environmental concerns: Propellants in inhalers pose ecological issues, prompting innovation in eco-friendly formulations.

3. Regulatory Landscape and Approvals

Regulatory Milestones

Year	Approval Body	Notable Approval	Notes
2017	FDA (USA)	GSK's Trelegy Ellipta (Fluticasone, Vilanterol, Umeclidinium)	Triple therapy, similar class
2018	EMA (Europe)	Trimbow (Budesonide, Formoterol, Glycopyrrolate)	First triple formulation approved in Europe
2020s	Ongoing approvals	Additional formulations & indications	Especially for once-daily dosing

Regulatory Challenges

• Demonstrating bioequivalence and safety in complex inhaled drug combinations.
• Navigating differing approvals across regions.

4. Competitive Landscape and Major Players

Company	Key Products	Market Share (%)	R&D Focus
GlaxoSmithKline	Trelegy Ellipta	~35	Inhaler device innovation, expanding indications
Chiesi Farmaceutici	Trimbow	Growing	Biosimilar inhaled formulations
AstraZeneca	Symbicort	Significant	Combination therapies for respiratory diseases
Novartis	Ultibro, Onbrez	Moderate	LAMA/LABA therapies
Boehringer Ingelheim	Spiriva (Glycopyrrolate)	Significant	LAMA monotherapy and combination formulations

5. Financial Projections and Revenue Streams

Market Size and Forecasts

Year	Global Market Size (USD billion)	CAGR (%)	Notes
2022	$3.2	—	Baseline
2027	$4.4	6-8	Driven by 신규 approvals, volume growth
2030	$5.9	~9	Innovation and adoption accelerate

Revenue Breakdown

Component	Approximate Contribution (%)	Notes
Budesonide	~40	ICS component, key reference drug
Formoterol	~35	Long-acting bronchodilator
Glycopyrrolate	~25	Anticholinergic agent

Note: Revenue from fixed-dose products and inhaler devices constitutes a significant portion (~70%) of recent product sales.

Impact of Patent Expirations

Patents on first-generation formulations expire between 2022-2025. Generics and biosimilars entering the market could reduce prices by 20-50%, pressuring profit margins.

6. Market Segmentation and Geographic Trends

Segmentation by Disease

Disease Type	Market Share (%)	Key Drivers
COPD	65	Aging populations, pollution, smoking prevalence
Asthma	35	Urbanization, allergen exposure

Regional Trends

Region	Market Size (USD billion, 2022)	CAGR (2022-2027)	Notable Factors
North America	$1.0	5-7	High prevalence, insurance coverage, FDA approvals
Europe	$0.9	6-8	Regulatory stringency, environmental policies
Asia-Pacific	$0.8	8-10	Rapid disease burden growth, unmet needs
Latin America & Africa	$0.5	10+	Growing awareness, access improvements

7. Emerging Innovation and Pipeline Developments

Novel Formulations and Technologies

• Once-daily combination inhalers: Improved adherence.
• Eco-friendly inhalers: Propellant-free formulations.
• Smart inhalers: Digital adherence tracking.

Pipeline Products

Candidate	Developer	Phase	Target Indication	Expected Benefits
Next-gen triple inhaler	GSK, Chiesi	Phase 3	COPD, asthma	Better delivery, fewer side effects
Bioequivalent generics	Multiple	Approved	COPD, asthma	Reduced costs, increased accessibility

Potential Disruptive Technologies

• Gene therapy: Long-term disease modification.
• Biologic agents: Targeted cytokine inhibitors.

8. Strategic Implications for Stakeholders

• Pharmaceutical companies:

  • Prioritize pipeline innovation, especially eco-friendly inhalers.
  • Expand geographic presence in emerging markets.
  • Invest in digital compliance tools.

• Investors:

  • Identify companies with strong R&D pipelines and robust patent portfolios.
  • Monitor regulatory milestones and patent cliffs.

• Regulatory bodies:

  • Streamline approval pathways for combination inhalers.
  • Promote sustainability initiatives in inhaler manufacturing.

• Healthcare providers:

  • Emphasize adherence strategies.
  • Advocate for eco-friendly therapies.

---

9. Key Takeaways

• The pharmaceutical market for Budesonide, Formoterol Fumarate, and Glycopyrrolate is poised for steady growth, driven by increasing respiratory disease burden and innovation.
• Patent expirations and the rise of biosimilars are likely to induce price competition, creating opportunities for generics.
• Regulatory approvals, such as the EU’s 2018 approval of Trimbow, underscore the trend toward triple inhalers in COPD and asthma care.
• Asia-Pacific represents the fastest-growing regional market, whereas mature regions like North America and Europe provide substantial revenue streams.
• Environmental sustainability and digital health integration are emerging competitive differentiators.

---

10. FAQs

Q1: What are the primary challenges in commercializing combination inhalers like those containing Budesonide, Formoterol, and Glycopyrrolate?

A: Challenges include demonstrating bioequivalence, navigating complex regulatory pathways, patent litigation, device design complexities for consistent delivery, and managing environmental concerns associated with inhaler propellants.

Q2: How do patent expirations influence the market for these drugs?

A: Patent expirations open the market to generic and biosimilar competitors, typically reducing prices by 20-50%. This increases access but pressures incumbent brand revenues.

Q3: What role does geographical diversification play in the financial success of these therapies?

A: Diversification reduces regional risk, taps into high-growth markets like Asia-Pacific, and capitalizes on unmet needs, thereby stabilizing revenue streams and optimizing global market share.

Q4: What technological innovations are expected to shape future inhaler therapies?

A: Innovations include once-daily combination inhalers, eco-friendly devices, and smart inhalers with built-in adherence monitoring, all aimed at improving patient compliance and reducing environmental impact.

Q5: Which companies are best positioned to capitalize on upcoming market opportunities?

A: Firms like GSK, Chiesi, and AstraZeneca possess strong R&D pipelines, extensive intellectual property, and global market access, positioning them favorably for future growth.

---

References

1. WHO. Global Surveillance, Prevention, and Control of Chronic Respiratory Diseases. 2017.
2. IMS Health. Respiratory Drug Market Analysis. 2022.
3. EMA. Approval of Trimbow (Budesonide/Formoterol/Glycopyrrolate). 2018.
4. GSK Annual Reports. Product Portfolio and Pipeline. 2022.
5. MarketWatch. Respiratory Disease Therapeutics Market Trends. 2023.

---

In summary, the market for Budesonide; Formoterol Fumarate; Glycopyrrolate combinations is on a growth trajectory dictated by medical need, innovation, and strategic industry shifts. While challenges remain, particularly around patent cliffs and environmental concerns, opportunities abound in emerging markets, pipeline advancements, and technological integrations, promising a dynamic future landscape for stakeholders engaged in pulmonary therapeutics.